A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review)
- Authors:
- Liping Wang
- Lin Liu
- Da Huo
- Yixiang Zhang
-
Affiliations: Department of Oncology, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China, Department of Gynecology, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China, Department of Traditional Chinese Medicine, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China, Department of Respiratory Medicine, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China - Published online on: December 28, 2023 https://doi.org/10.3892/ol.2023.14210
- Article Number: 77
This article is mentioned in:
Abstract
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gu B, Shang X, Yan M, Li X, Wang W, Wang Q and Zhang C: Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol Oncol. 161:573–580. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society, . Endometrial cancer survival rates, by stage. https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html | |
|
Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al: Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al: ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Musacchio L, Boccia SM, Caruso G, Santangelo G, Fischetti M, Tomao F, Perniola G, Palaia I, Muzii L, Pignata S, et al: Immune checkpoint inhibitors: A promising choice for endometrial cancer patients? J Clin Med. 9:17212020. View Article : Google Scholar : PubMed/NCBI | |
|
National Cancer Institute, . Endometrial cancer treatment Physician Data Query (PDQ). 2021.Available online. http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/healthprofessional13–August. 2021 | |
|
NCCN Clinical Practice Guidelines in Oncology, . Available online. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf13–August. 2020 | |
|
Miller DS, Blessing JA, Lentz SS and Waggoner SE: A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol. 87:247–251. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fracasso PM, Blessing JA, Molpus KL, Adler LM, Sorosky JI and Rose PG: Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 103:523–526. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia AA, Blessing JA, Nolte S and Mannel RS; Gynecologic Oncology Group, : A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol. 111:22–26. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P and Alvarez RD: Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic oncology group trial 129-P. J Clin Oncol. 27:3104–3108. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, et al: American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin. 51:38–75; quiz 77–80. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, et al: Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 145:1719–1730. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, Li C, Wu L and Ma XX: Parity and endometrial cancer risk: A meta-analysis of epidemiological studies. Sci Rep. 5:142432015. View Article : Google Scholar : PubMed/NCBI | |
|
Dunneram Y, Greenwood DC and Cade JE: Diet, menopause and the risk of ovarian, endometrial and breast cancer. Proc Nutr Soc. 78:438–448. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F and Straif K; International Agency for Research on Cancer Handbook Working Group, : Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 375:794–798. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M, et al: Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist: Hip ratio, is causal for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 25:1503–1510. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A; Australian National Endometrial Cancer Study Group (ANECS), ; Perry JR, Attia J, et al: Evidence of a causal association between insulinemia and endometrial cancer: A mendelian randomization analysis. J Natl Cancer Inst. 107:djv1782015. View Article : Google Scholar : PubMed/NCBI | |
|
Marlson MJ, Thiel KW, Yang S and Leslie KK: Catch it before it kills: Progesterone, obesity, and the prevention of endometrial cancer. Discov Med. 14:215–222. 2012.PubMed/NCBI | |
|
Khandekar MJ, Cohen P and Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 11:886–895. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE and Ioannidis JP: Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 350:g76072015. View Article : Google Scholar : PubMed/NCBI | |
|
Buchanan EM, Weinstein LC and Hillson C: Endometrial cancer. Am Fam Physician. 80:1075–1080. 2009.PubMed/NCBI | |
|
Parazzini F, La Vecchia C, Moroni S, Chatenoud L and Ricci E: Family history and the risk of endometrial cancer. Int J Cancer. 59:460–462. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M and Järvinen HJ: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 64:430–433. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R and Jenkins MA: Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer. 127:2678–2684. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM and Swisher E: Cowden syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. J Natl Cancer Inst. 105:1607–1616. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, Zhu H and Wang B: Cigarette smoking and the risk of endometrial cancer: A meta-analysis. Am J Med. 121:501–508.e3. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Loerbroks A, Schouten LJ, Goldbohm RA and van den Brandt PA: Alcohol consumption, cigarette smoking, and endometrial cancer risk: Results from the Netherlands Cohort Study. Cancer Causes Control. 18:551–560. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lindemann K, Vatten LJ, Ellstrøm-Engh M and Eskild A: Body mass, diabetes and smoking, and endometrial cancer risk: A follow-up study. Br J Cancer. 98:1582–1585. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL and Fishman J: Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 315:1305–1309. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat T: Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 26:1635–1648. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Wilczyński M, Danielska J and Wilczyński J: An update of the classical Bokhman's dualistic model of endometrial cancer. Prz Menopauzalny. 15:63–68. 2016.PubMed/NCBI | |
|
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A and Matias-Guiu X: Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 145:200–207. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Oaknin A, León-Castillo A and Lorusso D: Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): Data and perspectives. Curr Opin Oncol. 32:471–480. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, et al: A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 113:299–310. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Mamalis A, Garcha M and Jagdeo J: Targeting the PD-1 pathway: A promising future for the treatment of melanoma. Arch Dermatol Res. 306:511–519. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Chen W, Xu ZP and Gu W: PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 10:20222019. View Article : Google Scholar : PubMed/NCBI | |
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Post CCB, Westermann AM, Bosse T, Creutzberg CL and Kroep JR: PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol. 152:1029732020. View Article : Google Scholar : PubMed/NCBI | |
|
Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, Yang S, Li H, Zhou L and You Z: Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 12:944–950. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, et al: Clinicopathologic significance of mismatch repair defects in endometrial cancer: An NRG Oncology/Gynecologic oncology group study. J Clin Oncol. 34:3062–3068. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW and Roychowdhury S: Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget. 8:7452–7463. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, et al: Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 6:e12645652016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, Ono R, Sasamori H, Minamoto T, Iida K, et al: Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget. 9:5652–5664. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Piulats JM and Matias-Guiu X: Immunotherapy in endometrial cancer: In the nick of time. Clin Cancer Res. 22:5623–5625. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, et al: Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 38:3841–3850. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M and Yaegashi N: Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol. 22:636–642. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J, et al: Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 138:18–23. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results From the KEYNOTE-028 study. J Clin Oncol. 35:2535–2541. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J and Lifton RP: Regression of chemotherapy-resistant polymerase ε (POLE) Ultra-mutated and MSH6 Hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res. 22:5682–5687. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, Nomura H and Minami H: Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. Cancer Sci. 110:2894–2904. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kasherman L, Ahrari S and Lheureux S: Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 17:877–892. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, et al: Clinical activity and safety of the anti-programmed Death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical Trial. JAMA Oncol. 6:1766–1772. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, et al: Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 154:314–322. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, et al: Phase II Study of Avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 37:2786–2794. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, Spurdle A, Barnes E, Lee YC, Friedlander M, et al: Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 9:e0022552021. View Article : Google Scholar : PubMed/NCBI | |
|
Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S and Valabrega G: Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity. Oncotarget. 8:90532–90544. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, et al: Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 14:e02125132019. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC and Motzer RJ: Phase IB/II trial of Lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 38:1154–1163. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 38:2981–2992. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lheureux S, Matei D, Konstantinopoulos PA, Block MS, Jewell A, Gaillard S, McHale MS, McCourt CK, Temkin S, Girda E, et al: A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol. 38:60102020. View Article : Google Scholar | |
|
Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, Lambaudie E, Olive D and Sabatier R: Endometrial carcinoma: Immune microenvironment and emerging treatments in immuno-oncology. Biomedicines. 9:6322021. View Article : Google Scholar : PubMed/NCBI | |
|
Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E and Ghiringhelli F: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. BMC Cancer. 20:7482020. View Article : Google Scholar : PubMed/NCBI | |
|
Green AK, Feinberg J and Makker V: A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 40:1–7. 2020.PubMed/NCBI | |
|
Zitvogel L, Kepp O and Kroemer G: Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 8:151–160. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu WM, Fowler DW, Smith P and Dalgleish AG: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 102:115–123. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, et al: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 36:1611–1618. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I and Lecanda F: Radiation effects on antitumor immune responses: Current perspectives and challenges. Ther Adv Med Oncol. 10:17588340177425752018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee L and Matulonis U: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? Gynecol Oncol. 154:236–245. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, et al: PRIMMO study protocol: A phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer. 19:5062019. View Article : Google Scholar : PubMed/NCBI | |
|
Grandin M, Meier M, Delcros JG, Nikodemus D, Reuten R, Patel TR, Goldschneider D, Orriss G, Krahn N, Boussouar A, et al: Structural decoding of the Netrin-1/UNC5 interaction and its therapeutical implications in cancers. Cancer Cell. 29:173–185. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Paradisi A, Creveaux M, Gibert B, Devailly G, Redoulez E, Neves D, Cleyssac E, Treilleux I, Klein C, Niederfellner G, et al: Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. EMBO Mol Med. 5:1821–1834. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pakish JB and Jazaeri AA: Immunotherapy in gynecologic cancers: Are We there yet? Curr Treat Options Oncol. 18:592017. View Article : Google Scholar : PubMed/NCBI | |
|
Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH and Yates MS: Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. 23:4473–4481. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, et al: Advanced and recurrent endometrial cancer: State of the art and future perspectives. Crit Rev Oncol Hematol. 180:1038512022. View Article : Google Scholar : PubMed/NCBI | |
|
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, et al: Uterine Neoplasms, Version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 21:181–209. 2023. View Article : Google Scholar : PubMed/NCBI |
